Majority shareholders in Almirall, Spain's biggest drugmaker, have registered with the CNMV, Spain's securities commission, their intention to purchase up to an additional 5% of the firm's stock over the next 12 months. Antonio and Jorge Gallardo along with Daniel Bravo, want to show the market their "confidence and trust" in the firm. The investors will acquire the shares through Grupo Plafin and Todasa, which currently own 45% and 25% of the company, respectively.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze